Accelerating Drug Discovery With High-Throughput Crystallographic Fragment Screening and Structural Enablement

Applied Research Pub Date : 2024-11-24 DOI:10.1002/appl.202400192

Daren Fearon, Ailsa Powell, Alice Douangamath, Alexandre Dias, Charles W. E. Tomlinson, Blake H. Balcomb, Jasmin C. Aschenbrenner, Anthony Aimon, Isabel A. Barker, José Brandão-Neto, Patrick Collins, Louise E. Dunnett, Michael Fairhead, Richard J. Gildea, Mathew Golding, Tyler Gorrie-Stone, Paul V. Hathaway, Lizbé Koekemoer, Tobias Krojer, Ryan M. Lithgo, Elizabeth M. Maclean, Peter G. Marples, Xiaomin Ni, Rachael Skyner, Romain Talon, Warren Thompson, Conor F. Wild, Max Winokan, Nathan David Wright, Graeme Winter, Elizabeth J. Shotton, Frank von Delft

{"title":"Accelerating Drug Discovery With High-Throughput Crystallographic Fragment Screening and Structural Enablement","authors":"Daren Fearon, Ailsa Powell, Alice Douangamath, Alexandre Dias, Charles W. E. Tomlinson, Blake H. Balcomb, Jasmin C. Aschenbrenner, Anthony Aimon, Isabel A. Barker, José Brandão-Neto, Patrick Collins, Louise E. Dunnett, Michael Fairhead, Richard J. Gildea, Mathew Golding, Tyler Gorrie-Stone, Paul V. Hathaway, Lizbé Koekemoer, Tobias Krojer, Ryan M. Lithgo, Elizabeth M. Maclean, Peter G. Marples, Xiaomin Ni, Rachael Skyner, Romain Talon, Warren Thompson, Conor F. Wild, Max Winokan, Nathan David Wright, Graeme Winter, Elizabeth J. Shotton, Frank von Delft","doi":"10.1002/appl.202400192","DOIUrl":null,"url":null,"abstract":"<p>Fragment-based drug discovery is a well-established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low-throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead-like molecules.</p>","PeriodicalId":100109,"journal":{"name":"Applied Research","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/appl.202400192","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/appl.202400192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Fragment-based drug discovery is a well-established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low-throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead-like molecules.

Abstract Image